NOTV Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

Total Revenue: $120.9 million, up 0.8% from $119.9 million in Q1 2025.
DSA Revenue: $48 million, a 12% increase year-over-year, driven by a 26% rise in discovery pharmacology services.
RMS Revenue: $72.9 million, down 5.4% from the prior year, primarily due to a 25% decline in NHP (Non-Human Primate) volumes.
Operating Loss: Increased to $16.3 million from $15.5 million in Q1 2025.
Net Loss: $28.4 million, or $0.83 per diluted share, compared to a loss of $27.6 million, or $1.02 per diluted share, in Q1 2025.
Adjusted EBITDA: $1.8 million, or 1.5% of total revenue, down from $2.6 million, or 2.2% of revenue in Q1 2025.
Cash Position: $12.7 million as of December 31, 2025, down from $21.7 million at the end of Q4 2025.
Total Debt: Increased to $405.8 million from $402.1 million at the end of Q4 2025.

2. Strategic Updates and Business Highlights:

DSA Business Growth: Continued strong performance with a book-to-bill ratio of 1.16:1 for the quarter and 1.08:1 for the trailing 12 months. DSA awards increased by 27% year-over-year.
Site Optimization: The company exited two leased facilities as part of its RMS site optimization plan, expected to enhance margins moving forward.
Innovative Collaborations: Announced partnerships to integrate machine learning tools for better data analysis and access to human tissue, enhancing their NAMs (New Approach Methods) strategy.
Cost Reduction Initiatives: Ongoing efforts to streamline operations and reduce costs in the RMS segment.

3. Forward Guidance and Outlook:

No Formal Guidance: The company is not providing formal financial guidance for FY 2026 due to uncertainties in market demand and evolving tariff policies. However, management expressed optimism about the DSA segment's growth and margin improvements in the latter half of the fiscal year.

4. Challenges and Points of Concern:

RMS Segment Struggles: Continued challenges in the RMS business, particularly with NHP sales, which are expected to remain flat for FY 2026. The decline in NHP volumes significantly impacted overall revenue and margins.
Increased Operating Loss: The operating loss widened, primarily due to reduced RMS revenue and ongoing operational costs.
Cash Utilization: The company is relying on its revolving credit facility, indicating potential liquidity concerns.

5. Notable Q&A Insights:

Profitability Concerns: Management acknowledged that RMS margins were impacted by lower NHP volumes and increased operational costs, with expectations for improvement in the second half of the fiscal year.
DSA Awards Growth: Management attributed the positive trend in DSA awards to improved customer relationships and a focus on timely service delivery, which has led to increased recurring sales.
Seasonality Effects: Management noted that Q1 is typically weaker due to seasonal factors, including holidays and weather impacts on operations.
NHP Volume Decline: The 25% year-over-year decline in NHP volumes was highlighted as a significant factor affecting the RMS segment's performance.

Overall, while Inotiv is experiencing growth in its DSA business, challenges in the RMS segment, particularly with NHP sales, and increasing operational losses raise concerns about the company's financial health and future performance.

NOTV — Inotiv, Inc.